Amneal Pharmaceuticals, Inc. (AMRX)

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.

Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current market environment may also lie in its non-cyclical nature, thanks to resilient demand that is more related to health needs and demographics than to external economic conditions.

BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal

BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL).

BRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of Amneal's sodium oxybate oral solution 500 mg/mL Abbreviated New Drug Application (ANDA) which references Jazz Pharmaceuticals' Xyrem®.

For my initial rating of Amneal Pharmaceuticals (AMRX), I am calling it a buy. I was impressed by its large, diversified portfolio of therapies across clinical segments, and active pipeline of future potential drugs. While some profit margins and negative equity could use improvement, the company issued improved guidance for EPS and cashflow.

BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen's Risperdal Consta®. The product is eligible for 180-day exclusivity under the FDA's Competitive Generic Therapy (CGT) designation. Product launch is planned for the fourth quarter of 2025.

The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Amneal (AMRX) Q2 EPS Jumps 56%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Anastasios G. Konidaris - Executive VP & CFO Anthony DiMeo - Head of Investor Relations Chintu Patel - Co-Founder, Co-CEO & Director Chirag K.

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.